Compare Cipla with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs UNICHEM LAB - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA UNICHEM LAB CIPLA/
UNICHEM LAB
 
P/E (TTM) x 23.1 58.7 39.4% View Chart
P/BV x 2.4 0.6 374.0% View Chart
Dividend Yield % 0.7 2.2 31.1%  

Financials

 CIPLA   UNICHEM LAB
EQUITY SHARE DATA
    CIPLA
Mar-19
UNICHEM LAB
Mar-19
CIPLA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs678292 232.2%   
Low Rs484182 265.8%   
Sales per share (Unadj.) Rs198.2167.7 118.2%  
Earnings per share (Unadj.) Rs18.5-3.6 -510.2%  
Cash flow per share (Unadj.) Rs35.05.9 588.8%  
Dividends per share (Unadj.) Rs3.004.00 75.0%  
Dividend yield (eoy) %0.51.7 30.6%  
Book value per share (Unadj.) Rs186.3372.3 50.1%  
Shares outstanding (eoy) m805.7070.38 1,144.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.91.4 207.3%   
Avg P/E ratio x31.4-65.3 -48.0%  
P/CF ratio (eoy) x16.639.9 41.6%  
Price / Book Value ratio x3.10.6 489.7%  
Dividend payout %16.2-110.2 -14.7%   
Avg Mkt Cap Rs m468,03116,680 2,805.9%   
No. of employees `00022.62.6 870.3%   
Total wages/salary Rs m28,5652,393 1,193.6%   
Avg. sales/employee Rs Th7,053.14,535.2 155.5%   
Avg. wages/employee Rs Th1,261.5919.8 137.2%   
Avg. net profit/employee Rs Th659.1-98.2 -671.1%   
INCOME DATA
Net Sales Rs m159,71011,801 1,353.4%  
Other income Rs m4,766984 484.3%   
Total revenues Rs m164,47512,785 1,286.5%   
Gross profit Rs m30,973-835 -3,709.8%  
Depreciation Rs m13,263674 1,968.7%   
Interest Rs m1,68475 2,239.8%   
Profit before tax Rs m20,791-600 -3,467.0%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,695-343 -1,658.2%   
Profit after tax Rs m14,924-256 -5,840.6%  
Gross profit margin %19.4-7.1 -274.1%  
Effective tax rate %27.457.3 47.8%   
Net profit margin %9.3-2.2 -431.5%  
BALANCE SHEET DATA
Current assets Rs m124,26620,384 609.6%   
Current liabilities Rs m37,7155,029 749.9%   
Net working cap to sales %54.2130.1 41.6%  
Current ratio x3.34.1 81.3%  
Inventory Days Days91105 86.5%  
Debtors Days Days95135 70.3%  
Net fixed assets Rs m105,1909,023 1,165.8%   
Share capital Rs m1,611141 1,144.5%   
"Free" reserves Rs m148,51126,058 569.9%   
Net worth Rs m150,12326,199 573.0%   
Long term debt Rs m38,3010-   
Total assets Rs m239,63331,496 760.8%  
Interest coverage x13.3-7.0 -191.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.4 177.9%   
Return on assets %6.9-0.6 -1,210.5%  
Return on equity %9.9-1.0 -1,019.3%  
Return on capital %11.8-2.0 -592.1%  
Exports to sales %34.769.4 50.0%   
Imports to sales %00-   
Exports (fob) Rs m55,4198,188 676.8%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,4108,188 701.1%   
Fx outflow Rs m19,041596 3,194.8%   
Net fx Rs m38,3687,592 505.4%   
CASH FLOW
From Operations Rs m16,911-3,278 -516.0%  
From Investments Rs m-16,687-2,860 583.4%  
From Financial Activity Rs m-3,487-24 14,409.9%  
Net Cashflow Rs m-3,451-4,690 73.6%  

Share Holding

Indian Promoters % 16.0 50.1 31.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 15.1 80.8%  
FIIs % 23.7 3.0 790.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 31.7 82.6%  
Shareholders   161,166 20,176 798.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Energy & Realty Stocks Lead(09:30 am)

Asian share markets are higher today as Britain and the EU made headway on a Brexit deal ahead of a leaders' summit.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 16, 2019 10:37 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS